RxDoctor Payments Data

Stanley Kraus, MD

Urology · Framingham, MANPI 1720086713

Payments from drug & device makers

$9,747in general payments, 2019–2025

Across 396 payments — averaging $24.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Johnson & Johnson$975
  • Pfizer$915
  • Sumitomo Pharma America, Inc.$754
  • Tolmar, Inc.$592
  • Teleflex LLC$570
  • plus $5K from 45 others

What the payments were for

  • Food & beverage$9,00792%
  • Education$7408%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,747 in reported general payments places this provider in the 80th percentile of 327 urology providers in Massachusetts.

See all urology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$568,777
Medicare patients
601
Services billed
10,782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron17$15,851
Tamsulosin Hcl141$2,515
Cefpodoxime Proxetil29$1,646
Testosterone25$1,246
Estradiol16$843
Finasteride42$697
Silodosin14$656
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim150$584
Ciprofloxacin Hcl76$405
Trimethoprim14$356
Doxycycline Hyclate23$203
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst15$138
NitrofurantoinNitrofurantoin Macrocrystal14$136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$754$15,85117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 327 urology providers in Massachusetts.

Other urology in Framingham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →